Ask AI

Optimizing Treatment Sequencing in HER2-Positive Metastatic Breast Cancer

Video
This activity is available for 0.50 CME/CE credit(s).

Released: October 09, 2026

Expiration: April 08, 2027

See Activity Collection

This video module examines the rapidly evolving treatment landscape for HER2-positive metastatic breast cancer, focusing on evidence from key clinical trials that are reshaping first-line therapy, maintenance strategies, and treatment sequencing. Explore how emerging data on HER2-directed therapies inform individualized treatment decisions, including when to incorporate T-DXd, tucatinib, and other targeted approaches, how to navigate limited evidence following T-DXd progression, and how to integrate systemic and local therapies for patients with CNS metastases.

HER2 mBC Treatment Sequencing

Pre Assessment

Assess your current knowledge and clinical approach before beginning your video.
1.

How many people with breast cancer do you provide care for in a typical month?

2.

For those who practice in academic or community settings, please indicate your practice setting:

3.

A 58-year-old woman is newly diagnosed with HER2-positive metastatic breast cancer involving the liver and has asymptomatic brain metastases. Which of the following guideline recommended regimens would you consider as a first-line treatment option for this patient that has demonstrated superior PFS compared with THP, with benefit also observed in patients with baseline brain metastases?

4.

A patient with HER2-positive breast cancer previously received neoadjuvant trastuzumab plus chemotherapy and completed HER2-directed therapy 2 years ago. She now develops metastatic disease. When discussing treatment options, what would you tell them about first-line T-DXd + pertuzumab?